Biomarker Applications in Hepatocellular Carcinoma Diagnostics

Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, in part because of challenges in early detection and accurate staging. Biomarkers have emerged as pivotal tools to complement imaging modalities, enabling earlier diagnosis, prognostic stratification and monitoring of therapeutic response. Traditional serum markers such as alpha-fetoprotein (AFP) offer limited sensitivity and specificity, particularly in early-stage disease and in the context of underlying cirrhosis. Recent advances have expanded the biomarker repertoire to include panels of small metabolites, autoantibody signatures and tissue-derived molecules detectable in blood. Integrative approaches combining omics technologies—metabolomics, proteomics and transcriptomics—are refining the molecular landscape of HCC. Single-cell and spatial transcriptomic analyses are uncovering cell-type-specific expression of candidate markers and delineating tumour microenvironment interactions that influence biomarker release. Metabolite profiling in serum has identified distinct signatures differentiating early HCC from cirrhosis, while panels of tumour-associated autoantibodies exploit immune responses to nascent neoplastic cells for non-invasive detection. Combined biomarker algorithms are now demonstrating improved diagnostic accuracy over AFP alone, with potential to guide surveillance in at-risk populations, predict response to locoregional and systemic therapies and anticipate recurrence after curative interventions. Continued validation in diverse cohorts and harmonisation of assay platforms will be essential for translation into routine clinical workflows, with the ultimate goal of reducing HCC-related mortality by facilitating timely and personalised management.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Biomarker Applications in Hepatocellular Carcinoma Diagnostics publication trend

The graph below shows the total number of articles in biomarker applications in hepatocellular carcinoma diagnostics across all publications each year (not limited to Nature Index journals).

Technical terms

Biomarker: A measurable molecule indicating normal or pathological processes, used for diagnosis or monitoring of disease.

Alpha-fetoprotein (AFP): A glycoprotein produced by foetal liver cells, conventionally measured in adults as a marker for HCC.

Metabolomics: The systematic study of small-molecule metabolite profiles in biological specimens to characterise physiological or pathological states.

Autoantibody: An antibody produced by the immune system that recognises an individual’s own proteins, which can serve as indirect markers of tumour antigens.

Spatial transcriptomics: A technique that maps gene expression across tissue sections to preserve the spatial context of cell populations.

References

1. Integrating Single-Cell and Spatial Transcriptomics to Uncover and Elucidate GP73-Mediated Pro-Angiogenic Regulatory Networks in Hepatocellular Carcinoma. Research (2024).
2. Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis. Cancers (2019).
3. Autoantibody signature in hepatocellular carcinoma using seromics. Journal of Hematology & Oncology (2020).